Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas

Robbert D. A. Weren, Arjen R. Mensenkamp, Michiel Simons, Astrid Eijkelenboom, Aisha S. Sie, Hicham Ouchene, Monique van Asseldonk, Encarna B. Gomez-Garcia, Marinus J. Blok, Joanne A. de Hullu, Marcel R. Nelen, Alexander Hoischen, Johan Bulten, Bastiaan B. J. Tops, Nicoline Hoogerbrugge, Marjolijn J. L. Ligtenberg*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)226-235
Number of pages10
JournalHuman Mutation
Volume38
Issue number2
DOIs
Publication statusPublished - Feb 2017

Keywords

  • ovarian cancer
  • BRCA1
  • BRCA2
  • cancer predisposition
  • BRCA testing
  • personalized medicine
  • PARP-inhibitor
  • single molecule molecular inversion probes
  • MOLECULAR INVERSION PROBES
  • RANDOMIZED PHASE-2 TRIAL
  • POLY(ADP-RIBOSE) POLYMERASE
  • SOMATIC MUTATIONS
  • PREDICTS SENSITIVITY
  • CANCER INCIDENCE
  • RISK-ASSESSMENT
  • BREAST
  • GERMLINE
  • OLAPARIB

Cite this

Weren, R. D. A., Mensenkamp, A. R., Simons, M., Eijkelenboom, A., Sie, A. S., Ouchene, H., van Asseldonk, M., Gomez-Garcia, E. B., Blok, M. J., de Hullu, J. A., Nelen, M. R., Hoischen, A., Bulten, J., Tops, B. B. J., Hoogerbrugge, N., & Ligtenberg, M. J. L. (2017). Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Human Mutation, 38(2), 226-235. https://doi.org/10.1002/humu.23137